Introduction
Human papillomavirus (HPV) infection drives virtually all cervical cancer cases, yet a highly preventable disease continues to claim more than 350,000 lives annually, predominantly in low- and middle-income countries (LMICs) 4. Despite the existence of effective vaccines, high-performance screening assays, and curative treatments for precancerous lesions, a series of persistent gaps across the prevention-to-surveillance continuum undermines global elimination goals. The World Health Organization (WHO) has set the "90-70-90" targets by 2030: 90% of girls fully vaccinated against HPV by age 15, 70% of women screened with a high-performance test by ages 35 and 45, and 90% of women with cervical disease receiving treatment 4. Current evidence reveals that each of these targets remains unmet, and that attrition at every stage of the care cascade—from invitation to treatment—significantly undermines population-level outcomes 1.
1. Screening and Diagnostic Delays
Primary Screening Modality and Coverage
International guidelines have converged on HPV DNA detection as the preferred primary screening modality. The European Commission (updated February 2025) strongly recommends HPV detection testing over cytology or co-testing for organized population-based programs targeting individuals aged 30–50 years (strong recommendation, high-certainty evidence) 25. The WHO, ASCCP, ACOG, and China's 2025 national guidelines similarly endorse primary HPV testing, with 5-year screening intervals for HPV testing and 3-year intervals for cytology 2427. Real-world evidence supports this consensus: in Hunan Province, China, among 6.37 million eligible women, HPV testing achieved a CIN2+ (cervical intraepithelial neoplasia grade 2 or worse) detection rate of 0.604% versus 0.324% for liquid-based cytology (p<0.05)—an 86% higher yield 3.
Despite this evidence base, cytology remains predominant in many settings. In Hunan, 80.5% of screened women underwent cytology as the primary approach and only 19.5% received HPV testing 3, illustrating a substantial implementation gap even within a large national program. HPV positivity rates (12.2% for HPV vs. 3.85% ASC-US or worse for cytology) reflect superior sensitivity but demand robust triage infrastructure to avoid overreferral 3.
Time-to-Colposcopy and Demographic Disparities
Diagnostic delay following a positive HPV screen represents one of the most quantifiable and consequential practice gaps. A Kaiser Permanente Southern California study of 5,833 women with HPV screening results requiring colposcopy showed that only 71% completed colposcopy within 3 months and 78% within 6 months—meaning approximately 22–29% of women did not meet recommended timeframes 13. Notably, non-Hispanic Black women (risk ratio [RR] = 0.93; 95% CI 0.87–1.00) and women from the most socioeconomically deprived neighborhoods (RR = 0.95; 95% CI 0.90–1.00) were significantly less likely to complete colposcopy within 3 months compared with non-Hispanic White women and women from least-deprived areas, respectively 13. Women with HPV 16/18 or high-grade cytology were more likely to complete colposcopy promptly (RR 1.21–1.34), suggesting that clinical urgency signals partially override structural barriers but do not eliminate them.
Specimen Quality as a Hidden Gap
In resource-limited settings, specimen inadequacy compounds diagnostic delays. A mixed-methods study from Limpopo Province, South Africa found district-level Pap smear inadequacy rates of 38–50%, driven by inadequate professional nurse training in collection, labeling, and storage 15. These failures generate false-negative results, necessitate repeat screening visits, and delay diagnosis—directly undermining program effectiveness and creating inequitable outcomes for already underserved populations.
2. Triage Strategy Performance and Overreferral
HPV-based primary screening increases direct colposcopy referrals approximately two-fold compared with cytology, while the majority of HPV-positive women with low-grade cytology harbor no clinically significant disease 2. Among 194 HPV-positive women with ASC-US/LSIL in the IMPROVE trial (Netherlands), 73.2% had no CIN2+, 15.5% had CIN2, and only 11.3% had CIN3 2. This diagnostic inefficiency underscores the urgent need for effective triage.
The following table summarizes key triage performance metrics from cited studies:
| Triage Strategy | Population | CIN3+ Sensitivity | Specificity/PPV | Colposcopy Referral Reduction | Source |
|---|---|---|---|---|---|
| HPV16/18 genotyping AND FAM19A4/miR124-2 methylation | HPV-positive women with BMD/ASC-US/LSIL-equivalent cytology, Dutch screening cohorts | NPV 98.1–99.4% after 1-year cytology | for combined HPV16/18/31/33/45 + methylation, sensitivity 96.5%, specificity 29.5% | 95% direct reduction vs. refer-all | 2 |
| p16/Ki-67 dual stain | HPV+ women (China, 599 patients) | 91.6% for CIN2+ | Specificity 95.0%; AUC 0.932 | 34% reduction in unnecessary colposcopies | 22 |
| p16/Ki-67 dual stain | HR-HPV+ Chinese women (n=295) | 90.0% for CIN2+; 92.9% for CIN3+ | Specificity 71.6%; PPV 87.0% | Superior to HPV16/18 alone and LBC | 23 |
| Extended HPV genotyping + p16/Ki-67 | Chinese screening cohort (n=899+858) | Maintained vs. p16/Ki-67 alone | Referral rate 40.1% | Equivalent sensitivity/specificity | 21 |
| Cytology as triage (HPV+, Latin America) | 4,087 women, 490 CIN3+ (ESTAMPA) | 58.9% with HPV knowledge | Specificity 78.9% with HPV knowledge | — | 6 |
Cytology triage in HPV-positive women remains particularly problematic in Latin America: sensitivity for CIN3+ increased by only 11.7 percentage points when cytopathologists knew the HPV result (47.2% to 58.9%), while specificity fell substantially from 89.4% to 78.9% 6. This performance was highly variable across study centers (sensitivity range 36.1%–93.4%), confirming that cytology is an unreliable triage instrument in resource-limited settings without standardized quality control. By contrast, p16/Ki-67 dual staining demonstrates sensitivity of 91.6% and specificity of 95.0% for CIN2+ detection, substantially outperforming both cytology (sensitivity 42.1%) and HPV DNA testing alone (specificity 41.6%) 22. Both China's 2025 guidelines and the Dutch methylation evidence support moving toward molecular biomarker-based triage to reduce overreferral while maintaining detection accuracy 227.
3. Undertreatment and Loss to Follow-Up
The Care Cascade and Attrition at Each Stage
A structured monitoring framework developed at the University of British Columbia and BC Cancer identifies four cascade stages—screening, triage, detection, and treatment—at each of which attrition compounds into substantially reduced program effectiveness 1. The WHO target of 90% treatment completion contrasts sharply with real-world data showing that loss to follow-up (LTFU) operates as a compounding failure across all stages.
The EMPOWER Study, evaluating HPV self-collection among unhoused individuals in Austin, Texas (May–October 2024), provides a striking illustration. Of 87 participants who collected samples, only 52.9% received their results despite repeated contact attempts; of the 21 who tested high-risk HPV positive, only 4 (19.0%) underwent colposcopy 18. This cascade represents an 81% loss at colposcopy referral among HPV-positive individuals—a near-total failure of linkage to care in a vulnerable population despite successful initial screening uptake.
Modeling data from East African immigrant women in Washington State reinforce this dynamic quantitatively. An exclusive self-sampling strategy, despite achieving 70% screening coverage (vs. 63% for standard of care), resulted in 4% higher cervical cancer incidence and mortality when colposcopy adherence fell from 83% to 67% 10. Self-sampling only outperformed standard of care when colposcopy adherence was restored to standard levels and/or when screening coverage exceeded 90% 10. These findings demonstrate that expanding screening access without concurrent strengthening of follow-up systems can paradoxically worsen population outcomes.
The Canadian modeling context similarly quantifies the stakes: increasing screening participation from 70% to 90% or improving colposcopy attendance could accelerate cervical cancer elimination by 2 years 1. Early cancer diagnosis without timely treatment also causes patient harm, and treatment delay is explicitly recognized as a clinical problem independent of diagnostic access 9.
4. Self-Sampling: Opportunity and Limitations
HPV self-vaginal sampling (SVS) represents the most promising structural intervention for improving screening access, particularly for populations with historical barriers to clinician-based collection, including marginalized communities, older postmenopausal women, and rural populations 5. Consensus guidelines from the Enduring Consensus Cervical Cancer Screening and Management Guidelines Committee now accept self-collected vaginal specimens for primary HPV screening of asymptomatic average-risk individuals, with repeat testing recommended at 3 years following HPV-negative results 7. Triage pathways by HPV genotype apply equivalently: HPV 16/18-positive self-collected results warrant colposcopy with cytology and biopsies; non-16/18 types require clinician-collected cytology or dual stain; HPV 56/59/66-positive results warrant repeat HPV testing at 1 year 7.
However, evidence from a rural Ethiopia pilot demonstrates the implementation complexity of self-sampling programs. Of 749 enumerated eligible women, only 57.2% provided adequate samples for HPV DNA testing, with 25.2% of initial samples insufficient and 31.9% of re-collection attempts successful 20. Triage clinic attendance among HPV-positive women reached 71.7%, but yield at colposcopy identified CIN3 in only 2 of 38 attending women (5.3%), consistent with low-prevalence screening populations 20. A postmenopausal Swedish cohort further illustrates molecular triage specificity problems: HPV prevalence was 3.4% in professionally collected samples versus 12.6% in self-collected samples, and while sensitivity for high-grade squamous intraepithelial lesion (HSIL) was preserved, molecular triage (methylation plus genotyping) resulted in twice as many colposcopy referrals as cytology, with specificity deemed "unacceptably low" 14.
Key implementation concerns documented in the consensus guideline include that minimal data exist on self-sampling for surveillance after abnormal results, colposcopy, or treatment, making clinician-collected specimens preferable for post-treatment follow-up 7. The Isbaar Project, targeting Somali American individuals using HPV self-sampling in Minneapolis primary care clinics from February 2023, demonstrates the organizational complexity of community-embedded implementation and is evaluating outcomes using RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) frameworks 8.
5. HPV Vaccination: Coverage Gaps and Long-Term Efficacy
A randomized clinical trial (ICI-VPH) enrolling 3,356 girls in Québec found that a 2-dose schedule of quadrivalent HPV vaccine (4vHPV) provided robust protection against persistent HPV-16 and HPV-18 infection for up to 13 years, with no cases of persistent HPV-16/18 in the 2-dose group and only one time-limited persistent infection in the 2+1-dose booster group (0.1%) 19. The booster dose at 60 months conferred no additional clinical benefit, validating the 2-dose schedule's durability 19. Despite this immunological efficacy, the WHO resolution (WHA78.8) explicitly acknowledges that HPV vaccination coverage in girls under 15 years is "far from the goal of 90% by 2030," with equity concerns particularly acute for persons with disabilities and those in rural or humanitarian settings 4. Vaccination campaigns must be complemented by continued screening for all women regardless of vaccination status, as full population-level impact will not be measurable for decades 24.
6. Post-Treatment Surveillance Gaps
Post-treatment surveillance represents an underemphasized component of the HPV management continuum. Test-of-cure protocols—typically HPV testing at 1 and 3 years after excision or ablation—are recommended to detect recurrence, yet adherence data across settings is limited in the retrieved literature. The p16/Ki-67 dual stain has demonstrated utility specifically in post-treatment surveillance scenarios: it identified 4 women with high-grade lesions detected by diagnostic conization but with negative colposcopy-guided biopsies 22, suggesting a role for biomarker-based surveillance beyond standard cytology in complex cases. The consensus guideline explicitly notes that self-collected specimens are not yet validated for post-treatment surveillance, maintaining a preference for clinician-collected samples in this setting 7. Monitoring frameworks identify treatment completion and post-treatment follow-up rates as distinct metrics requiring targeted program tracking and benchmark comparison 1.
7. Guideline Variability and Implementation Implications
| Guideline Body | Primary Screening Recommendation | Triage Approach | Self-Sampling | Key Update |
|---|---|---|---|---|
| USPSTF (2018) | Cytology q3y (21–29); HPV alone, co-test, or cytology q3–5y (30–65) | Per ASCCP protocols | Not specified | No update in retrieval period |
| European Commission (Feb 2025) | HPV detection only; cytology NOT recommended | Organized programs with quality assurance | Recognized for access improvement | Strong recommendation, high certainty |
| WHO (2nd edition) | HPV DNA detection first-choice globally | Screening-triage-treatment or screen-and-treat | PCR-based self-collection preferred | Immediate treatment for HPV+ where capacity limited |
| China (2025) | hrHPV nucleic acid detection first-choice (age 25–64, q5y) | HPV16/18 → direct colposcopy; others → cytology/dual stain triage | Emerging in 2025 consensus landscape | p16/Ki-67 appears 2A; methylation 2B |
| ASCCP (USPSTF-aligned) | HPV primary screening preferred (ages 25+) | Risk-based; HPV16/18 → colposcopy | Self-collected vaginal specimens acceptable for primary HPV screening | 2025 Practice Advisory on self-collection |
The most material divergence is the European Commission's 2025 strong recommendation against cytology and co-testing as primary screening modalities 25, which contrasts with USPSTF and ACOG maintaining cytology as an acceptable option 24. China's 2025 guidelines align most closely with WHO by designating hrHPV detection as the first-choice method while pragmatically allowing cytology where HPV infrastructure is unavailable 27. This variability creates implementation inconsistencies, particularly for healthcare systems in transition, and requires investment in laboratory capacity, workforce training, and quality assurance infrastructure to realize the promised gains of HPV-based screening.
8. Actionable Interventions and Implementation Priorities
Evidence supports the following prioritized interventions:
-
Mailed or community-delivered HPV self-sampling kits for underscreened populations (reaching Somali Americans, unhoused individuals, rural populations) to improve initial coverage, but only when paired with robust patient navigation and follow-up linkage systems to prevent paradoxical increases in cancer incidence from LTFU 81018.
-
p16/Ki-67 dual-stain triage for HPV-positive women to replace cytology triage where cytology quality control is inadequate, achieving 34% reduction in unnecessary colposcopy referrals while preserving 91.6% sensitivity for CIN2+ 2216.
-
Extended HPV genotyping combined with molecular biomarkers (methylation or dual stain) for precision risk stratification, reducing direct colposcopy referrals by up to 95% in low-grade cytology populations while maintaining ≥98% NPV (negative predictive value) after 1-year repeat testing 221.
-
Cascade monitoring frameworks with stage-specific benchmarks (screening reach, triage completion, colposcopy attendance, treatment initiation within 6 months) to identify which cascade stage drives program underperformance and to target SMS reminders, patient navigators, or same-day screen-and-treat models accordingly 14.
-
Standardized specimen collection training and quality assurance in LMIC settings, where inadequacy rates of 38–50% represent a fundamental barrier to program effectiveness requiring structured in-service education and supervision 15.
-
Population-based cancer and screening registries to measure progress toward WHO 90-70-90 targets, enable electronic reminder systems, and reduce fragmented records that contribute to LTFU 41.
Conclusion
The HPV management continuum is undermined by compounding attrition at each stage—from incomplete vaccination coverage, to delayed colposcopy after positive screening, to inadequate post-treatment surveillance. Quantified gaps include 22–29% of women failing to complete colposcopy within 6 months 13, 81% LTFU at colposcopy among HPV-positive unhoused individuals 18, 38–50% specimen inadequacy rates in South African rural facilities 15, and cytology triage sensitivity for CIN3+ as low as 47.2% in Latin American programs 6. Each gap translates into delayed CIN3+ detection, continued invasive cervical cancer incidence in underserved populations, and treatment completion rates below WHO targets. Addressing these gaps requires simultaneous investment in validated screening technologies (primary HPV testing, molecular triage biomarkers), structural access interventions (self-sampling with navigation), workforce capacity building, and data infrastructure—integrated within equity-centered implementation frameworks that ensure no woman is left behind along the prevention-to-surveillance continuum 4125.